Drug developer Sepracor Inc. said Friday it has applied to market the insomnia treatment Lunivia in the European Union. via Boston Globe
From Insomnia News
“The company is swimming against the tide”
Sepracor may represent a good takeover target, said analyst Jon LeCroy of Natexis Bleichroeder Inc. via Telegram & Gazette
From Insomnia News
“The question now is can they get sales moving again and can they cut costs?”
Sepracor Inc. posted lower-than-expected second-quarter earnings on Friday and cut its outlook as competitive and reimbursement pressures hurt sales of its asthma and insomnia drugs, sending its shares down … via BNET
From Insomnia News
“Eisai is one of Japan’s largest and most respected pharmaceutical companies, and we are delighted to have established this partnership with such a well-regarded company”
Sepracor Inc. today announced an agreement with Eisai Co. Ltd. for the development and commercialization of Sepracor’s eszopiclone product, which is known in the U.S. by the brand name LUNESTA, for the Japanese … via BioSpace
From Insomnia News
Eisai Co., Ltd. and Sepracor Inc. signed an in-licensing agreement for the insomnia treatment eszopiclone ) on July 26, 2007 . via Customer Interaction Solutions
From Insomnia News
If this is a troubling question for you, then you may be one of many people suffering from insomnia. via Seattle Post-Intelligencer
From Insomnia News
Insomnia sleep apnea is treatable and can be controlled. The first thing that needs to be done is an insomnia sleep apnea test. via Tips and Answers
From Insomnia News
“An inverted posture is simply getting your legs above your heart and/or your head and neck below your heart”
Insomniacs will learn ways to naturally fall and stay asleep in ‘Insomnia: How to Sleep Better Without Drugs,’ an Aug. via Daily Record
From Insomnia News
“The patients are mostly between early-20s and late-40s.”
He slogs it out for 15 hours a day in office. But when he returns home dead tired, sleep remains elusive. via The Telegraph
From Insomnia News
“I expect [more than a] double [in the stock price] if it gets approval and a similar drop if it does not.”
Clinical-stage drug developer Arena Pharmaceuticals reported its second-quarter earnings yesterday. via Fool.com
From Insomnia News
Sleep Disorder Information
